Loading
Screening finds cancers that would never have caused harm alongside dangerous ones. Pair every screening test with a test that says which is which, so people with harmless findings can safely watch and wait.
Overdiagnosis in prostate, thyroid, breast (DCIS) and low-dose CT lung screening leads to unnecessary surgery and anxiety and is the main argument against expanding screening. Molecular and imaging classifiers of indolence (genomic classifiers in prostate cancer, DCIS risk scores, radiomic and growth-rate models for lung nodules, ctDNA fragmentomics) are emerging but not integrated into programmes. The proposal is that every screening programme develops, validates and deploys an indolence classifier with a surveillance-first protocol for low-risk findings, and reports overdiagnosis as a monitored quality metric.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms, Thyroid cancer, Prostate cancer.
Shares Overdiagnosis in cancer, AI in radiology, Overdiagnosis and false alarms, Non-small-cell lung cancer.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms, Thyroid cancer, Prostate cancer.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms, Thyroid cancer.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms, HR-positive / HER2-negative breast cancer.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms, Thyroid cancer.
Shares Overdiagnosis in cancer, Multi-cancer early detection (MCED), Overdiagnosis and false alarms.
Shares Stage shift, AI in radiology, Overdiagnosis and false alarms, The hardest cancers are found late.